Búsqueda | Biblioteca Virtual en Salud Odontología. Uruguay

1.

Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer.

Aggarwal, Ritesh K; Luchtel, Rebecca A; Machha, Venkata; Tischer, Alexander; Zou, Yiyu; Pradhan, Kith; Ashai, Nadia; Ramachandra, Nandini; Albanese, Joseph M; Yang, Jung-In; Wang, Xiaoyang; Aluri, Srinivas; Gordon, Shanisha; Aboumohamed, Ahmed; Gartrell, Benjamin A; Hafizi, Sassan; Pullman, James; Shenoy, Niraj.

Proc Natl Acad Sci U S A ; 118(39)2021 09 28.

Artículo en Inglés | MEDLINE | ID: mdl-34551979

2.

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.

Luchtel, Rebecca A; Bhagat, Tushar; Pradhan, Kith; Jacobs, William R; Levine, Mark; Verma, Amit; Shenoy, Niraj.

Proc Natl Acad Sci U S A ; 117(3): 1666-1677, 2020 01 21.

Artículo en Inglés | MEDLINE | ID: mdl-31911474

3.

Immune evasion in renal cell carcinoma: biology, clinical translation, future directions.

Wang, Xiaoyang; Lopez, Robert; Luchtel, Rebecca A; Hafizi, Sassan; Gartrell, Benjamin; Shenoy, Niraj.

Kidney Int ; 99(1): 75-85, 2021 01.

Artículo en Inglés | MEDLINE | ID: mdl-32949550

4.

Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting?

Shenoy, Niraj; Luchtel, Rebecca; Gulani, Perminder.

BMC Med ; 18(1): 260, 2020 08 19.

Artículo en Inglés | MEDLINE | ID: mdl-32814566

5.

Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer.

Bhagat, Tushar D; Zou, Yiyu; Huang, Shizheng; Park, Jihwan; Palmer, Matthew B; Hu, Caroline; Li, Weijuan; Shenoy, Niraj; Giricz, Orsolya; Choudhary, Gaurav; Yu, Yiting; Ko, Yi-An; Izquierdo, María C; Park, Ae Seo Deok; Vallumsetla, Nishanth; Laurence, Remi; Lopez, Robert; Suzuki, Masako; Pullman, James; Kaner, Justin; Gartrell, Benjamin; Hakimi, A Ari; Greally, John M; Patel, Bharvin; Benhadji, Karim; Pradhan, Kith; Verma, Amit; Susztak, Katalin.

J Biol Chem ; 292(3): 837-846, 2017 01 20.

Artículo en Inglés | MEDLINE | ID: mdl-27909050

6.

Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells.

Shenoy, Niraj; Stenson, Mary; Lawson, Joshua; Abeykoon, Jithma; Patnaik, Mrinal; Wu, Xiaosheng; Witzig, Thomas.

Lab Invest ; 97(5): 494-497, 2017 05.

Artículo en Inglés | MEDLINE | ID: mdl-28240748

7.

Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity?

Shenoy, Niraj; Dronca, Roxana; Quevedo, Fernando; Boorjian, Stephen A; Cheville, John; Costello, Brian; Kohli, Manish; Witzig, Thomas; Pagliaro, Lance.

Chin J Cancer Res ; 29(4): 374-378, 2017 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-28947870

8.

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Wang, Yuan; Lieberman, Rachel; Pan, Jing; Zhang, Qi; Du, Meijun; Zhang, Peng; Nevalainen, Marja; Kohli, Manish; Shenoy, Niraj K; Meng, Hui; You, Ming; Wang, Liang.

Mol Cancer ; 15(1): 70, 2016 11 10.

Artículo en Inglés | MEDLINE | ID: mdl-27832783

9.

Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Shenoy, Niraj; Vallumsetla, Nishanth; Rachmilewitz, Eliezer; Verma, Amit; Ginzburg, Yelena.

Blood ; 124(6): 873-81, 2014 Aug 07.

Artículo en Inglés | MEDLINE | ID: mdl-24923296

10.

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.

Shenoy, Niraj; Kohli, Manish.

Indian J Urol ; 32(4): 257-261, 2016.

Artículo en Inglés | MEDLINE | ID: mdl-27843206

11.

Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy.

Shenoy, Niraj.

Cancer ; 126(24): 5198-5201, 2020 12 15.

Artículo en Inglés | MEDLINE | ID: mdl-33048366

12.

Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin.

Shenoy, Niraj; Tesfaye, Melaku; Brown, Joshua; Simmons, Nichelle; Weiss, Deborah; Meholli, Mimoza; Mabie, Peter.

Pract Neurol ; 15(4): 289-92, 2015 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-25935926

13.

Derivative survival analyses: Analysis methods to derive survival outcomes for the remainder patient cohort without individual patient data.

Shenoy, Niraj K.

Cell Rep Med ; 5(4): 101500, 2024 Apr 16.

Artículo en Inglés | MEDLINE | ID: mdl-38582084

14.

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.

Serritella, Anthony V; Shenoy, Niraj K.

JAMA Oncol ; 9(10): 1441-1446, 2023 Oct 01.

Artículo en Inglés | MEDLINE | ID: mdl-37651124

15.

Neurological applications of belzutifan in von Hippel-Lindau disease.

Zhang, Yue; Nguyen, Catherine C; Zhang, Nigel T; Fink, Nicolas S; John, Jordan D; Venkatesh, Omkar G; Roe, Jonathan D; Hoffman, Steven C; Lesniak, Maciej S; Wolinsky, Jean-Paul; Horbinski, Craig; Szymaniak, Brittany M; Buerki, Robin A; Sosman, Jeffrey A; Shenoy, Niraj K; Lukas, Rimas V.

Neuro Oncol ; 25(5): 827-838, 2023 05 04.

Artículo en Inglés | MEDLINE | ID: mdl-36215167

16.

Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?

Shenoy, Niraj.

Chin J Cancer Res ; 29(2): 166-167, 2017 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-28536496

17.

Is ADRM1 a Good Target for Cancer Therapy?

Shenoy, Niraj.

Acta Haematol ; 134(2): 86-7, 2015.

Artículo en Inglés | MEDLINE | ID: mdl-25895922

18.

HIF1α is not a target of 14q deletion in clear cell renal cancer.

Shenoy, Niraj.

Sci Rep ; 10(1): 17642, 2020 10 19.

Artículo en Inglés | MEDLINE | ID: mdl-33077781

19.

Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid.

Shenoy, Niraj.

Mol Cell Oncol ; 6(3): 1595309, 2019.

Artículo en Inglés | MEDLINE | ID: mdl-31131312

20.

Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma-Reply.

Shenoy, Niraj K.

JAMA Oncol ; 10(4): 536, 2024 Apr 01.

Artículo en Inglés | MEDLINE | ID: mdl-38300549

Biblioteca Virtual en Salud Odontología. Uruguay

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer.

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.

Immune evasion in renal cell carcinoma: biology, clinical translation, future directions.

Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting?

Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer.

Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells.

Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity?

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.

Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy.

Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin.

Derivative survival analyses: Analysis methods to derive survival outcomes for the remainder patient cohort without individual patient data.

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.

Neurological applications of belzutifan in von Hippel-Lindau disease.

Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?

Is ADRM1 a Good Target for Cancer Therapy?

HIF1α is not a target of 14q deletion in clear cell renal cancer.

Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid.

Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma-Reply.